- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fischer's Q2 revenues climb 21%
Fischer Imaging saw revenues jump 21% for its second quarter (end-June)due to continued success in selling systems through its OEM partners.The Denver company also saw net income more than double in theperiod. For the quarter, Fischer reported sales of
Fischer Imaging saw revenues jump 21% for its second quarter (end-June)due to continued success in selling systems through its OEM partners.The Denver company also saw net income more than double in theperiod.
For the quarter, Fischer reported sales of $21.9 million, upsharply from the $18.1 million posted in the second quarter of1995. Net income stood at $946,000, compared with $397,000 inthe same period the year before.
Fischer chairman and CEO Morgan Nields reported that Fischer'sSenoScan full-field digital mammography program is moving forward:Fischer is planning to ship its second clinical trial unit inthe next several weeks, with clinical trials to follow. Fischerplans to submit a regulatory application for the system in thesecond half of this year, with clearance expected in 1997.
Fischer earlier this month completed a secondary stock offeringthat raised $13.5 million. The company is now virtually debt-freeand has cash on hand to fund growth opportunities, according toCFO Jim Newcomb.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
